Definium study shows anxiety disorder prevalence rose to 6.6% in 2023
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq rise as tech, chipmakers rebound
- Oil prices settle $1 higher after Iran and Israel say they have halted attacks
- Tech stocks gain as Trump mulls government stake in AI companies
- Morgan Stanley’s Wilson calls Friday U.S. selloff a "healthy reset"
- Hedge funds loaded up on equities ahead of sharp Friday drop
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Salesforce to acquire metering platform M3TER for consumption billing
- SpaceX sets $135 price for blockbuster IPO, upending Wall Street convention
- Quantum Space to go public via $1.2B SPAC merger
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States
March 31, 2026 7:00 AM EDTThe annual prevalence of newly diagnosed generalized anxiety disorder (GAD) increased from 5.4% in 2020 to 6.6% in 2023
The 3-year total prevalence of GAD reached 10.3%, representing more than 1 in 10 U.S. adults
NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (Definium or the Company), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world prevalence, incidence, and burden of GAD in the United States healthcare system from 2020 to 2023. These findings show a steadily increasing diagnosed prevalence of GAD and highlight a substantial and... More
